PepGen’s (PEPG) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PepGen (NASDAQ:PEPG) in a research note released on Monday,Benzinga reports. They currently have a $16.00 price objective on the stock. HC Wainwright also issued estimates for PepGen’s Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.74) EPS.

Several other analysts also recently commented on PEPG. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a research report on Monday, December 16th. Wedbush decreased their price target on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

PepGen Price Performance

NASDAQ:PEPG opened at $1.53 on Monday. The stock has a market cap of $49.87 million, a PE ratio of -0.51 and a beta of 1.53. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The stock’s 50-day moving average is $2.41 and its two-hundred day moving average is $5.75.

PepGen (NASDAQ:PEPG) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.13. On average, equities research analysts anticipate that PepGen will post -2.73 earnings per share for the current year.

Hedge Funds Weigh In On PepGen

A number of institutional investors have recently made changes to their positions in PEPG. RTW Investments LP acquired a new stake in PepGen in the 4th quarter valued at approximately $12,102,000. Janus Henderson Group PLC boosted its position in shares of PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after acquiring an additional 1,794,641 shares during the period. Millennium Management LLC grew its stake in shares of PepGen by 1,033.2% in the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after acquiring an additional 142,814 shares during the last quarter. Suvretta Capital Management LLC grew its stake in shares of PepGen by 9.2% in the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after acquiring an additional 140,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in PepGen during the fourth quarter worth $516,000. 58.01% of the stock is currently owned by institutional investors.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.